Intelligence / Healthtech / New Clinical Trials / Sanofi
Clinicaltrial registered5 Nov 2026
Sanofi
5 Nov 2026: Trial registered · Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and Berahyaluronidase Alfa (ALT-B4) Coformulation. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 5 Nov 2026
- Title
- Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and Berahyaluronidase Alfa (ALT-B4) Coformulation
- Conditions
- Dermatitis Atopic
- Phase
- Phase 3
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Reference
- NCT07919899
What this signal means
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at Sanofi
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for Sanofi in our registers.
18 NovSanofitrial registered · HealthtechClinical17 NovSanofitrial registered · HealthtechClinical12 NovSanofitrial registered · HealthtechClinical10 NovSanofitrial registered · HealthtechClinical6 NovSanofitrial registered · HealthtechClinical6 NovSanofitrial registered · HealthtechClinical30 OctSanofitrial registered · HealthtechClinical29 OctSanofitrial registered · HealthtechClinical29 OctSanofitrial registered · HealthtechClinical29 OctSanofitrial registered · HealthtechClinical27 OctSanofitrial registered · HealthtechClinical26 OctSanofitrial registered · HealthtechClinical
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.